On September 14, at the semi-annual results meeting, Jiankai Technology explained that the capacity utilization rate of the Panjin plant has increased compared to the same period last year. In addition to providing raw materials and intermediates for Tianjin Jiankai, it has already begun to steadily supply finished products to some new customers. In terms of LNP business, the company currently supplies LNP products or provides technical services related to LNP to about 200 LNP related customers at home and abroad. The vast majority of them are domestic customers in the early R&D stage, so the relevant revenue situation in the second half of the year needs to be based on actual order delivery. Currently, demand in the mRNA field is mainly in several directions, such as mRNA vaccines, in vivo CAR, and gene editing. In addition to selling products, the company also provides customers with supporting technical services such as customized services, quality research, and registration.

On September 14, at the semi-annual results meeting, Jiankai Technology explained that the capacity utilization rate of the Panjin plant has increased compared to the same period last year. In addition to providing raw materials and intermediates for Tianjin Jiankai, it has already begun to steadily supply finished products to some new customers. In terms of LNP business, the company currently supplies LNP products or provides technical services related to LNP to about 200 LNP related customers at home and abroad. The vast majority of them are domestic customers in the early R&D stage, so the relevant revenue situation in the second half of the year needs to be based on actual order delivery. Currently, demand in the mRNA field is mainly in several directions, such as mRNA vaccines, in vivo CAR, and gene editing. In addition to selling products, the company also provides customers with supporting technical services such as customized services, quality research, and registration.